Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease

Next Previous
Trial Profile

Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

Most Recent Events

  • 22 Mar 2016 Status changed from active, no longer recruiting to completed.
  • 23 Feb 2016 Planned End Date changed from 1 Jan 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
  • 08 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top